The treatment causes bruising and soreness at the injection site, but these side effects are usually mild and go away within a couple of weeks.
Scientific Claim
CCH-aaes is generally well tolerated in adult women with moderate-to-severe buttock cellulite, with the most common adverse events being injection-site bruising (84.4%) and injection-site pain (48.1%), which are predominantly mild to moderate and resolve within 14–21 days.
Original Statement
“The most common AEs with CCH-aaes treatment were injection-site-related, with injection-site bruising, injection-site pain, and injection-site nodule being the most common AEs... Most (92.6%) AEs in the CCH-aaes group were mild to moderate in intensity... Most treatment-related AEs were transient, with a mean duration of 14.7 days (median, 9.0 days).”
Evidence Quality Assessment
Claim Status
appropriately stated
Study Design Support
Design supports claim
Appropriate Language Strength
definitive
Can make definitive causal claims
Assessment Explanation
The study is a large RCT with comprehensive AE monitoring. The reported frequencies and durations are direct observations, making definitive descriptive claims appropriate.
Gold Standard Evidence Needed
According to GRADE and EBM methodology, here is what ideal scientific evidence would look like to definitively prove or disprove this specific claim, ordered from strongest to weakest evidence.
Systematic Review & Meta-AnalysisLevel 1aIn EvidenceConsistent safety profile of CCH-aaes across multiple RCTs and populations.
Consistent safety profile of CCH-aaes across multiple RCTs and populations.
What This Would Prove
Consistent safety profile of CCH-aaes across multiple RCTs and populations.
Ideal Study Design
A systematic review and meta-analysis of all phase 2–4 RCTs of CCH-aaes for cellulite, pooling incidence, severity, and duration of injection-site AEs (bruising, pain, nodules) across ≥1000 patients.
Limitation: Cannot detect rare or long-term adverse events beyond 3 months.
Randomized Controlled TrialLevel 1bIn EvidenceCausal comparison of AE rates between CCH-aaes and placebo.
Causal comparison of AE rates between CCH-aaes and placebo.
What This Would Prove
Causal comparison of AE rates between CCH-aaes and placebo.
Ideal Study Design
A double-blind RCT of 500 adult women with moderate-to-severe buttock cellulite randomized to CCH-aaes (0.84 mg ×3) or placebo, with daily AE logs for 30 days post-injection and standardized grading (CTCAE v5).
Limitation: Limited to short-term safety; excludes patients with bleeding disorders or prior skin trauma.
Prospective Cohort StudyLevel 2bReal-world frequency and persistence of AEs in routine clinical use.
Real-world frequency and persistence of AEs in routine clinical use.
What This Would Prove
Real-world frequency and persistence of AEs in routine clinical use.
Ideal Study Design
A prospective multicenter cohort study of 1000 women receiving CCH-aaes for buttock cellulite in dermatology practices, tracking AE incidence, severity, duration, and need for intervention over 6 months.
Limitation: No control group; potential for underreporting of mild events.
Case-Control StudyLevel 3bAssociation between patient factors (e.g., BMI, age) and risk of severe AEs.
Association between patient factors (e.g., BMI, age) and risk of severe AEs.
What This Would Prove
Association between patient factors (e.g., BMI, age) and risk of severe AEs.
Ideal Study Design
A case-control study comparing 100 women with severe injection-site reactions (e.g., prolonged nodules, infection) to 200 controls without, matched for age, BMI, and treatment history, to identify risk factors.
Limitation: Cannot establish causation; prone to selection bias.
In Vitro StudyLevel 5Mechanism of collagenase-induced local tissue inflammation or vascular damage.
Mechanism of collagenase-induced local tissue inflammation or vascular damage.
What This Would Prove
Mechanism of collagenase-induced local tissue inflammation or vascular damage.
Ideal Study Design
An in vitro study exposing human dermal microvascular endothelial cells and fibroblasts to CCH-aaes, measuring markers of inflammation (IL-6, TNF-α), apoptosis, and vascular permeability over 24–72 hours.
Limitation: Cannot replicate in vivo immune response or tissue architecture.
Evidence from Studies
Supporting (1)
Collagenase Clostridium Histolyticum-aaes for Treatment of Cellulite: A Pooled Analysis of Two Phase-3 Trials
This study gave a special injection to women with dimpled buttocks and found that most got bruising or pain at the injection site, but it wasn’t too bad and went away in a couple of weeks — just like the claim says.